IL17A and arthritic joint disease: Polymerized-Type I Collagen and methotrexate/Polymerized Collagen treatments had a sustained effect in early and established arthritis model until the second sacrifice (follow up) on the percentage of IL-17A-producing CD4+ T (Figures 4(b) and 4(d)).